Vision loss from inherited retinal diseases may become preventable through targeted protein enhancement, offering hope for millions facing genetic blindness. These conditions typically result from cellular stress caused by misfolded proteins, a process that damages light-sensing photoreceptors beyond repair.
Scientists used CRISPR gene editing to systematically test thousands of genes in mice carrying the P23H rhodopsin mutation, which causes the most common form of inherited blindness in Americans. Among the protective factors identified, two proteins—UFD1 and UXT—demonstrated remarkable ability to preserve both rod and cone photoreceptors when artificially boosted. Treated retinas maintained functional vision and improved behavioral responses to light stimuli. The researchers then validated these findings in human retinal tissue carrying the same mutation, where UFD1 and UXT enhancement prevented photoreceptor death.
This discovery represents a significant advance in retinal disease research because these proteins appear to work regardless of the specific genetic mutation causing vision loss. Most inherited eye diseases involve different genes but share a common pathway of protein misfolding and cellular toxicity. UFD1 and UXT likely combat this proteotoxicity through enhanced cellular quality control mechanisms. The human tissue model also accelerates clinical translation by providing a platform to test therapies before human trials. While promising, the approach requires delivery methods to boost these proteins in living eyes, and long-term safety remains unproven. The work nonetheless establishes a systematic framework for discovering neuroprotective strategies that could benefit the estimated 2 million people worldwide with inherited retinal diseases.